May 21, 2018   SOURCE: PR NewsWire

Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting

Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting

ROCKVILLE, Md. and HONG KONG, May 21, 2018 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018.

The poster sessions of APG-1252, a novel dual inhibitor of Bcl-2/Bcl-xL, and APG-1387, a IAP inhibitor, will be held on June 4.

"We are excited to present initial clinical experience with two of our pipeline candidates," commented Dr. Dajun Yang, Chairman and CEO of Ascentage. "These unique small molecules address complex, protein-protein interactions involved in apoptotic pathways in cancer. We look forward to continuing these single agent studies as well as combination trials with immunotherapy treatments."

ASCO abstracts include:

    --  Title: A Phase 1 Study of Novel dual Bcl-2/Bcl-xL Inhibitor APG-1252 in
        Patients with Advanced Small Cell Lung Cancer (SCLC) or Other Solid
        TumorSession Date and Time: Monday, June 4 at 8:00 a.m. - 11:30 a.m.
        CDTAbstract Number: 2594APG-1252 was designed to reduce the target
        platelet toxicity seen with dual inhibitors Bcl-2/Bcl-xL, while
        maintaining strong antitumor activity. Preliminary results showed that
        APG-1252 was well-tolerated with no hematologic toxicity reported. There
        was one confirmed partial response in a metastatic small cell lung
        cancer (SCLC) patient. Dose escalation continues in SCLC and other solid
        tumors.




    --  Title: A Phase 1 Study of a Novel IAP Inhibitor APG-1387 In Patients
        With Advanced Solid Tumors Session Date and Time: Monday, June 4 at 8:00
        a.m. - 11:30 a.m. CDTAbstract Number: 2593APG-1387 was well-tolerated
        with manageable adverse events. Preliminary responses indicated positive
        host immune responses, suggesting synergy with immunotherapy agents.
        Studies are continuing with APG-1387 in combination with immunotherapy
        agents in patients with advanced solid tumors or hematologic
        malignancies.

About Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

Media Contact
Amy Bonanno
E-mail: abonanno@bmccommunications.com
Phone: +1 914 450 0349

Investor Contact
Chad Rubin
E-mail: crubin@troutgroup.com
Phone: +1 646 378 2947

View original content:http://www.prnewswire.com/news-releases/ascentage-pharma-announces-promising-phase-1-interim-results-in-two-clinical-programs-to-be-presented-at-2018-asco-annual-meeting-300651363.html

SOURCE Ascentage Pharma